Sugi Predict

Sugi Predict / Compounds / SCHEMBL983433

SCHEMBL983433

SCHEMBL983433

COC(=O)c1cccc(NC(N)=S)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 1.00
▸ RAB9A P51151 4/20 0.70
▸ NPC1 O15118 3/20 0.70
▸ MAPT P10636 5/20 0.62
▸ SMN1; SMN2 Q16637 3/20 0.58
▸ TP53 P04637 1/20 0.58
▸ KMT2A Q03164 4/20 0.58
▸ LMNA P02545 1/20 0.58
▸ MEN1 O00255 3/20 0.57
▸ CYP1A2 P05177 2/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2D6 P10635 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ POLB P06746 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ HPGD P15428 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12835093 0.89 ALDH1A1 (0.79) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL308570 0.87 ALDH1A1 (0.77) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL260299 0.85 ALDH1A1 (0.74) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL1884508 0.85 ALDH1A1 (0.73) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL11756491 0.84 ALDH1A1 (0.72) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL27776624 0.84 RAB9A (0.76) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL7975430 0.84 ALDH1A1 (0.72) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL4531507 0.83 ALDH1A1 (0.71) ALDH1A1TP53KMT2AMEN1CYP1A2
SCHEMBL23455508 0.83 RAB9A (1.00) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL11654124 0.81 RAB9A (0.71) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101973960-B Improved method for preparing benzo[d][1,2,3] thiadiazole-7-formic acid trifluoroacetate UNIV EAST CHINA SCIENCE & TECH 2012-07-04 — — CN claimed
CN-101973960-A Improved method for preparing benzo[d][1,2,3] thiadiazole-7-formic acid trifluoroacetate UNIV EAST CHINA SCIENCE & TECH 2011-02-16 — — CN claimed
US-12060362-B2 Inhibitors of glucose transporters (GLUTs) LEAD DISCOVERY CENTER GMBH (DE) 2024-08-13 — — US disclosed
EP-3814359-B1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS) LEAD DISCOVERY CENTER GMBH (DE) 2022-08-17 — — EP disclosed
US-20210198269-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-07-01 — — US disclosed
US-20210198269-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2021-07-01 — — US disclosed
EP-3814359-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTS) Lead Discovery Center GmbH (DE) 2021-05-05 — — EP disclosed
EP-0780372-B3 3-Amino-2-mercaptobenzoic acid derivatives and processes for their preparation SYNGENTA PARTICIPATIONS AG (CH) 2013-05-22 — — EP disclosed
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 — — US disclosed
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 — — US disclosed
US-8236964-B2 Thiazolidine derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-08-07 — — US disclosed
US-6498265-B2 HAVING MICROBICIDAL AND PLANT-IMMUNIZING ACTION SYNGENTA INVESTMENT CORPORATION 2002-12-24 — — US disclosed
US-6380422-B1 MICROBIOCIDES; PLANT IMMUNIZING SYNGENTA INVESTMENT CORPORTION 2002-04-30 — — US disclosed
US-20020040157-A1 3-amino-2-mercaptobenzoic acid derivatives and processes for their preparation KUNZ WALTER (CH) 2002-04-04 — — US disclosed
EP-0780372-B1 3-Amino-2-mercaptobenzoic acid derivatives and processes for their preparation SYNGENTA PARTICIPATIONS AG (CH) 2001-11-14 — — EP disclosed
US-6002013-A 2-AMINO-7-CARBOXYBENZOTHIAZOLE DERIVATIVES NOVARTIS CORPORATION (US) 1999-12-14 — — US disclosed
US-5847147-A 3-Amino-2-mercaptobenzoic acid derivatives and processes for their preparation NOVARTIS CORP. (US) 1998-12-08 — — US disclosed
US-5770758-A MICROBIOCIDES, PLANT IMMUNIZING AGENTS NOVARTIS CORPORATION (US) 1998-06-23 — — US disclosed
CN-1156722-A 3-amino-2-mercaptobenzoic acid derivatives and process for preparing same CIBA GEIGY AG (CH) 1997-08-13 — — CN disclosed
EP-0780372-A2 3-Amino-2-mercaptobenzoic acid derivatives and processes for their preparation Novartis AG (CH) 1997-06-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12060362-B2 Inhibitors of glucose transporters (GLUTs) SLC2A1, SLC2A3, SLC2A4 ALDH1A1 364/4885RAB9A 3217/4885NPC1 549/4885
US-20020040157-A1 3-amino-2-mercaptobenzoic acid derivatives and processes for their preparation CBR3, CBR1, TST ALDH1A1 1788/4885RAB9A 1918/4885NPC1 2105/4885
US-20210198269-A1 INHIBITORS OF GLUCOSE TRANSPORTERS (GLUTs) SLC2A1, SLC2A3, SLC2A4 ALDH1A1 515/4885RAB9A 3223/4885NPC1 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.